Zydrox 500 mg Capsule
Brand Name: Zydrox
Molecule: Hydroxyurea
Strength: 500 mg
Quantity: 100 Capsules
Form: Capsule
Packaging Type: Strips
Manufacturer/Marketed By: Zuvius Lifesciences
Country of Origin: India
Please fill in the details below, and we’ll get back to you as soon as possible
Similar Products:
| Image | Product | Manufacturer / Marketed By | Price |
|---|---|---|---|
 | Myelostat 500 mg Capsule | Zydus Cadila | Ask for Price |
 | Hydrea 500 mg Capsule | Everest Pharma | Ask for Price |
Description
Zydrox 500 mg Capsule is an oral chemotherapy medicine containing Hydroxyurea, used to treat certain cancers and blood disorders. Manufactured by Zuvius Lifesciences, Zydrox belongs to a class of drugs called antimetabolites, which work by slowing or stopping the growth of abnormal cells in the body. Zydrox 500 mg is commonly prescribed for leukemia, sickle cell disease, and other conditions involving abnormal blood cell production. It is available in capsule form for convenient daily use under medical supervision.
Benefits
- Helps slow or stop cancer cell growth
- Controls abnormal blood cell production
- Reduces painful crises in sickle cell disease
- Improves overall disease management
- Easy-to-use oral capsule formulation
Indications and Usage
Zydrox 500 mg Capsule is used in the treatment of:
- Chronic Myeloid Leukemia (CML)
- Head and Neck Cancer
- Solid Tumors
- Sickle Cell Disease
- Polycythemia Vera (off-label)
- Essential Thrombocythemia (off-label)
It may also be used along with radiation therapy in selected cancer cases.
How it Works
Zydrox contains Hydroxyurea, which:
- Blocks an enzyme called ribonucleotide reductase
- Prevents DNA synthesis in rapidly dividing cells
- Stops the multiplication of cancer cells
This helps control disease progression and abnormal blood cell production.
Dosage & Administration
Use only as prescribed by your doctor.
General dosage guidelines:
- Cancer (Solid Tumors / Head & Neck):
- 20–30 mg/kg daily OR
- 80 mg/kg every 3 days
- Chronic Myeloid Leukemia:
- 20–30 mg/kg once daily
- Sickle Cell Disease:
- Starting dose: 15 mg/kg/day
- Gradual increase based on response
- Maximum: 35 mg/kg/day
Take the capsule with water, with or without food, at the same time each day.
Side Effects
Like all chemotherapy medicines, Hydroxyurea may cause side effects.
Common side effects:
- Nausea and vomiting
- Loss of appetite
- Constipation or diarrhea
- Weakness and fatigue
Serious side effects:
- Bone marrow suppression
- Low white blood cells (infection risk)
- Low platelets (bleeding risk)
- Mouth ulcers
- Skin darkening or rash
Regular blood tests (CBC) are required during treatment.
Warning and Precaution
- Avoid during pregnancy (risk of birth defects)
- Use reliable contraception during treatment
- Not recommended during breastfeeding
- Regular monitoring required:
- Blood counts
- Liver function
- Kidney function
- Increased risk of:
- Infections
- Secondary cancers (long-term use)
Patient Guidance
- Take exactly as prescribed
- Do not skip or double doses
- Stay hydrated
- Avoid exposure to infections
- Immediately report:
- Fever
- Bleeding
- Severe fatigue
Regular follow-ups and blood tests are essential.
Clinical Trial & Approvals
Hydroxyurea, the active ingredient in Zydrox, is:
- Widely used in oncology and hematology
- Clinically proven to:
- Reduce complications in sickle cell disease
- Improve control in leukemia
- Included in international treatment guidelines
FAQ
What is Zydrox 500 mg Capsule used for?
It is used to treat leukemia, sickle cell disease, and certain cancers.
Is Zydrox chemotherapy?
Yes, it is an oral chemotherapy medicine.
Can I take Zydrox daily?
Yes, if prescribed by your doctor.
Does it cure cancer?
It helps control the disease but may not cure it completely.
Is monitoring required?
Yes, regular blood tests are necessary.
Can I stop taking it suddenly?
No, always consult your doctor before stopping.
Related Products
Related Posts:
Bone Marrow Transplant: A Complete Guide for Patients
The realization that you or someone close to you needs a bone marrow transplant can be extremely daunting. It may
READ MORE »June 16, 2026
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.